Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BLACK DIAMOND THERAPEUTICS INC.
BDTX | US
2.18
USD-0.08
-3.54%
BDTX | US
Loading StockChartView...
About BLACK DIAMOND THERAPEUTICS INC.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
2.18
Open
2.25
High
2.27
Low
2.17
Black Diamond Therapeutics Inc. a clinical-stage precision oncology medicine company focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate BDTX-1535 a brain-penetrant mutant selective irreversible EGFR MasterKey inhibitor designed to inhibit a family of oncogenic mutations currently under Phase 1 clinical trial. It also develops BDTX-4933 a brain penetrant RAF MasterKey inhibitor designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I II III and active RAF dimers expected to initiate Phase 1 clinical trial. The company was formerly known as ASET Therapeutics Inc. and changed its name to Black Diamond Therapeutics Inc. in January 2018. Black Diamond Therapeutics Inc. was incorporated in 2014 and is headquartered in Cambridge Massachusetts.
View LessBDTX | US
Risk
167.1
Sharpe
-0.07
Luna's Score
36/100
Recommendation
Sell
Luna says (BDTX | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
235.1%1 month
167.1%3 months
113.5%6 months
94.5%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.64
Debt to equity
0.21
Debt to assets
0.16
Ent. to EBITDA
-1.92
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-86.87M
MarketCap
123.18M
MarketCap(USD)
123.18M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-83.38
Short ratio
3.00
Short perc.
20.59
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
1.80
Range1M
1.80
Range3M
2.04
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.65
Price X volume
2.97M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.92 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.64 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 113.47 | 72.80 | Riskier |
| Debt to Equity | 0.21 | -1.23 | Expensive |
| Debt to Assets | 0.16 | 0.25 | Cheaper |
| Market Cap | 123.18M | 3.66B | Emerging |
